{"_buckets": {"deposit": "060a9f71-3111-4557-8c75-59dd9d785cbe"}, "_deposit": {"id": "14271", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "14271"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00014271"}, "item_7_alternative_title_1": {"attribute_name": "\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_alternative_title": "Effects of Two Immunosuppressants, Cyclosporin A and Mizoribime, and Angiotansin Converting Enzyme Inhibitor, Enalapril on Alport Model Mice"}]}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2002-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "7", "bibliographicPageEnd": "336", "bibliographicPageStart": "324", "bibliographicVolumeNumber": "116", "bibliographic_titles": [{"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c"}, {"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Effective pharmacotherapy in Alport syndrome has not yet been established. In this study, the efficiency of two immunosuppressants cyclosporin A (CyA) and mizoribine (MZR), and angiotensin converting enzyme inhibitor (ACEi), enalapril was examined using Col4 \u03b1 4 knockout mice as a model of this disease. CyA (10mg/kg/day), MZR (50mg/kg/day) and enalapril (18mg/kg/day) were administered everyday from three weeks of age. The CyA and enalapril treatments suppressed the elevation of proteinuria at 8 and 12 weeks of age and significantly inhibited the crescent formation at 12 weeks of age. The enalapril treatment could prolong the lives of Col4 \u03b1 4 mutant mice significantly, i.e, 26.3\u00b16.2 weeks (mean\u00b1SD) of the treated mice vs. 18.3\u00b13.9 weeks of the untreated control mice, whereas the CyA treatment failed to prolong the life span. Taken together, enalapril is considered to have a beneficial effect on the Alport model mice. This effect may be brought about by the improvement of renal hemodynamics and the suppression of an antiadhesion factor tenascin.", "subitem_description_type": "Abstract"}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u65b0\u6f5f\u533b\u5b66\u4f1a"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u4f0a\u6771, \u9054\u96c4"}], "nameIdentifiers": [{"nameIdentifier": "92635", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KJ00000141921.pdf", "filesize": [{"value": "2.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2000000.0, "url": {"label": "KJ00000141921.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/14271/files/KJ00000141921.pdf"}, "version_id": "3e35d51a-8f09-4d4a-b5af-46172d50909f"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Alport syndrome", "subitem_subject_scheme": "Other"}, {"subitem_subject": "knockout mice", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cyclosporin A", "subitem_subject_scheme": "Other"}, {"subitem_subject": "angiotensin converting enzyme inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tenascin-C", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "\u30a2\u30eb\u30dd\u30fc\u30c8\u75c7\u5019\u7fa4\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306b\u5bfe\u3059\u308b\u85ac\u7269\u7642\u6cd5\u306e\u691c\u8a0e", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "\u30a2\u30eb\u30dd\u30fc\u30c8\u75c7\u5019\u7fa4\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306b\u5bfe\u3059\u308b\u85ac\u7269\u7642\u6cd5\u306e\u691c\u8a0e"}, {"subitem_title": "\u30a2\u30eb\u30dd\u30fc\u30c8\u75c7\u5019\u7fa4\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306b\u5bfe\u3059\u308b\u85ac\u7269\u7642\u6cd5\u306e\u691c\u8a0e", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/538/1061"], "permalink_uri": "http://hdl.handle.net/10191/2651", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2007-05-10"}, "publish_date": "2007-05-10", "publish_status": "0", "recid": "14271", "relation": {}, "relation_version_is_last": true, "title": ["\u30a2\u30eb\u30dd\u30fc\u30c8\u75c7\u5019\u7fa4\u30e2\u30c7\u30eb\u30de\u30a6\u30b9\u306b\u5bfe\u3059\u308b\u85ac\u7269\u7642\u6cd5\u306e\u691c\u8a0e"], "weko_shared_id": null}